Agios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 study
Biotech
Summary
Days after its lead clinical-stage asset suffered a setback, Agios Pharmaceuticals has rebounded by buying a blood disorder drug that flunked a phase 2 study.
Why It Matters
This Biotech development strengthens the region's biomanufacturing and life-sciences base. For South Korea, it is a signal worth tracking: it shapes who supplies, who scales, and who sets the standard over the next five years.
Key Facts
- SectorBiotech
- MarketSouth Korea
- ImpactMedium (56/100)
- SignalFunding Research